MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
China Pharma Holdings Cash and Cash Equivalents 2011-2025 | CPHI
Annual Cash and Cash Equivalents China Pharma Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 600 K | 1.42 M | 2.03 M | 4.86 M | 958 K | 1.07 M | 1.19 M | 2.03 M | 2.67 M | 6.25 M | 5.3 M | 5.99 M | 4.03 M | 4.05 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.25 M | 600 K | 3.03 M |
Quarterly Cash and Cash Equivalents China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 268 K | 600 K | 400 K | 627 K | 719 K | 739 K | 839 K | 1.42 M | 1.37 M | 902 K | 1.17 M | 2.03 M | 2.09 M | 2.24 M | 3.71 M | 4.86 M | 459 K | 1.75 M | 535 K | 958 K | 958 K | 958 K | 958 K | 1.07 M | 1.07 M | 1.07 M | 1.07 M | 1.19 M | 1.19 M | 1.19 M | 1.19 M | 2.03 M | 2.03 M | 2.03 M | 2.03 M | 2.67 M | 2.67 M | 2.67 M | 7.26 M | 6.25 M | 6.25 M | 6.25 M | 6.25 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.99 M | 5.99 M | 5.99 M | 4.75 M | 4.03 M | 5.06 M | 4.87 M | 3.32 M | 4.05 M | 4.05 M | 4.05 M | 4.05 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.26 M | 268 K | 2.8 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
73.4 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 1.64 | -5.64 % | $ 176 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8.86 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
138 M | $ 5.12 | -5.19 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
112 M | $ 12.12 | 6.13 % | $ 621 M | USA |
 |
Evoke Pharma
EVOK
|
4.74 M | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | $ 21.4 | 0.16 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
87 M | $ 7.16 | 1.7 % | $ 444 M | USA |
 |
Harrow Health
HROW
|
74.1 M | $ 46.04 | -2.17 % | $ 1.5 B | USA |
 |
Bausch Health Companies
BHC
|
947 M | $ 6.86 | -0.87 % | $ 2.5 B | Canada |
 |
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
136 M | $ 4.78 | -0.93 % | $ 629 M | USA |
 |
OrganiGram Holdings
OGI
|
24.6 M | $ 1.78 | -7.55 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
277 M | $ 26.49 | 0.76 % | $ 1.23 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 3.02 | 19.37 % | $ 42.5 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
148 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
8.98 M | $ 0.88 | -5.2 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
80.2 M | $ 5.8 | -1.28 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.09 M | $ 4.34 | 6.9 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
349 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
559 M | $ 12.83 | -2.36 % | $ 1.76 B | USA |
 |
ProPhase Labs
PRPH
|
9.11 M | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
24.9 M | $ 2.44 | 0.83 % | $ 329 M | USA |
 |
Sundial Growers
SNDL
|
218 M | $ 1.94 | -12.22 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
2.45 M | $ 1.25 | 4.17 % | $ 5.39 M | USA |
 |
SCYNEXIS
SCYX
|
34 M | $ 0.64 | -0.56 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
207 M | $ 11.11 | -8.56 % | $ 6.87 B | Canada |
 |
TherapeuticsMD
TXMD
|
4.33 M | $ 1.73 | -1.14 % | $ 18.1 M | USA |
 |
Zomedica Corp.
ZOM
|
13 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
1.26 B | $ 11.69 | 0.34 % | $ 14.2 B | USA |